8-K: Skye Bioscience Q3 2025: Nimacimab Shows Promising Obesity Data

Skye Bioscience reported its Q3 2025 financial results and positive topline data from its CBeyond Phase 2a study for nimacimab in obesity, highlighting significant weight loss and reduced rebound.

Summary

• Skye Bioscience reported financial results for the third quarter ended September 30, 2025.
• Topline data from the CBeyond Phase 2a study showed a 29% relative increase in weight loss when nimacimab was dosed in combination with semaglutide compared to semaglutide alone after 26 weeks.
• Nimacimab plus semaglutide combination achieved an additional decrease in waist circumference of 3.2 cm (1.25 inches) compared to semaglutide alone.
• Rebound weight gain was significantly lower in the 12-week post-treatment follow-up period for patients treated with nimacimab plus semaglutide (18.1%) versus semaglutide alone (49.8%).
• The study demonstrated a clean neuropsychiatric safety profile and no increase in gastrointestinal adverse events for nimacimab.
• The company is shifting its focus to a combination development pathway while also planning to further understand nimacimab's potential in a monotherapy setting.
• Enrollment for the 26-week extension study was completed in September, with 43 patients (19 in combination, 24 in monotherapy cohorts).
• Cash, cash equivalents, and short-term investments totaled $35.3 million as of September 30, 2025.
• Current capital is expected to fund projected operations and key clinical milestones into 2027.
• Research and development (R&D) expenses for Q3 2025 were $9.4 million, an increase from $4.9 million in Q3 2024.
• General and administrative (G&A) expenses for Q3 2025 were $3.9 million, a decrease from $4.6 million in Q3 2024.
• Net loss for Q3 2025 totaled $12.8 million, compared to $3.9 million for the same period in 2024.

Sentiment

Score: 8

Explanation: The clinical trial results for nimacimab are very positive, showing enhanced efficacy and reduced weight rebound when combined with semaglutide, alongside a favorable safety profile. This significantly de-risks the drug's development. While the net loss increased and R&D expenses rose, the extended cash runway into 2027 provides financial stability for continued development. The strategic shift to combination therapy is a strong positive.

Positives

• Nimacimab/semaglutide combination achieved a 29% relative increase in weight loss over semaglutide alone after 26 weeks, demonstrating enhanced efficacy.
• The combination therapy led to an additional 3.2 cm (1.25 inches) reduction in waist circumference, indicating improved body composition.
• Patients treated with nimacimab plus semaglutide experienced significantly lower rebound weight gain (18.1%) compared to semaglutide alone (49.8%) over 12 weeks post-treatment, addressing a major challenge in obesity management.
• Nimacimab demonstrated a clean neuropsychiatric safety profile and no increase in gastrointestinal adverse events, which is crucial for patient tolerability and market acceptance.
• Current capital of $35.3 million is projected to fund operations and key clinical milestones into 2027, providing a solid financial runway.
• General and administrative expenses decreased to $3.9 million in Q3 2025 from $4.6 million in Q3 2024, reflecting improved cost management in this area.

Negatives

• Net loss for Q3 2025 significantly increased to $12.8 million from $3.9 million in Q3 2024, indicating a higher burn rate.
• Research and development expenses increased substantially to $9.4 million in Q3 2025 from $4.9 million in Q3 2024, reflecting increased costs associated with clinical trials and development.
• Cash and cash equivalents decreased from $68.4 million at December 31, 2024, to $18.4 million at September 30, 2025, although short-term investments partially offset this.

Risks

• The initiation and design of any future clinical trials will be impacted by the company's capital resources and its ability to obtain additional sources of capital.
• There is no guarantee that additional weight loss after 26 weeks will ultimately be observed in ongoing or future studies.
• Higher dosing of nimacimab may not achieve increased efficacy and could potentially produce adverse safety and tolerability results.
• The company's dependence on third parties for product manufacturing, research, and preclinical and clinical testing introduces external dependencies.
• The ability to advance, obtain regulatory approval of, and ultimately commercialize nimacimab is subject to various uncertainties.
• Competitive products or approaches could limit the commercial value of nimacimab.
• The timing and results of preclinical and clinical trials are inherently uncertain.
• The company's ability to fund development activities and achieve development goals is critical and subject to financial constraints.
• External factors such as global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, and adverse regulatory changes could impact operations.
• The company's ability to protect its intellectual property is crucial for long-term success.
• Risks are associated with the company's common stock, including market volatility.

Future Outlook

Skye Bioscience anticipates that forthcoming biomarker data and the readout from the 26-week extension study in Q1 2026 will provide further insights into nimacimab's full potential as a metabolic therapy. The company expects its current capital to fund projected operations and key clinical milestones into 2027, including completion of the Phase 2a extension study, initial manufacturing runs needed to start a subsequent trial, and planning activities for nimacimab's later stage studies.

Management Comments

• "As we obtain additional data from our CBeyond Phase 2a study, a holistic review provides us with additional confidence that nimacimab's biology is active and has the potential to fill notable gaps in the obesity and overweight landscape in order to support a healthier weight loss journey for patients." Punit Dhillon, President & CEO.
• "With the positive combination data, we are shifting our focus to a combination development pathway while simultaneously planning to further understand nimacimab's potential benefit in a monotherapy setting." Punit Dhillon, President & CEO.
• "We anticipate that forthcoming biomarker data and the readout from the 26-week extension will continue to build upon this story and provide further insights into nimacimab's full potential as a metabolic therapy." Punit Dhillon, President & CEO.

Industry Context

The obesity treatment landscape is rapidly evolving, with GLP-1 receptor agonists like semaglutide (Wegovy) setting high benchmarks for weight loss. Skye Bioscience's nimacimab, a CB1 inhibitor, aims to differentiate itself by enhancing weight loss and improving body composition (targeting fat loss) when combined with GLP-1 therapeutics, without increasing gastrointestinal side effects. The focus on blunting rebound weight gain also addresses a significant challenge in long-term weight management, potentially positioning nimacimab as a valuable combination or maintenance therapy.

Comparison to Industry Standards

• Nimacimab's ability to achieve a 29% relative increase in weight loss when combined with semaglutide suggests a synergistic effect that could surpass the efficacy of semaglutide monotherapy, which typically achieves 15-20% total body weight loss in clinical trials (e.g., Wegovy's STEP trials).
• The additional 3.2 cm reduction in waist circumference with the combination therapy indicates an improved body composition profile, potentially targeting visceral fat more effectively than GLP-1s alone, which is a key differentiator in metabolic health.
• The significantly lower rebound weight gain (18.1% vs. 49.8%) in the nimacimab plus semaglutide group addresses a major unmet need in obesity management, as weight regain is a common challenge after discontinuing GLP-1 therapies. This could position nimacimab as a crucial maintenance therapy.
• The clean neuropsychiatric safety profile and lack of increased gastrointestinal adverse events are critical, as some obesity drugs have faced safety concerns (e.g., early CB1 inhibitors like Rimonabant were withdrawn due to psychiatric side effects) and GLP-1s are known for GI side effects. This profile could offer a competitive advantage.

Stakeholder Impact

• Shareholders: Positive clinical data could increase investor confidence and potentially share price. Increased net loss and R&D expenses represent a higher burn rate, but the extended cash runway mitigates immediate concern.
• Patients (Obesity/Overweight): Nimacimab, especially in combination with semaglutide, offers potential for more effective weight loss, improved body composition, and reduced weight regain, addressing significant unmet needs.
• Employees: Continued development and positive clinical results provide job security and potential for growth within the company.
• Suppliers/Partners: Increased R&D and manufacturing activities could lead to more business for contract manufacturers and clinical research organizations.

Next Steps

• Further understand nimacimab's potential benefit in a monotherapy setting.
• Anticipate forthcoming biomarker data.
• Readout from the 26-week extension study expected in Q1 2026.
• Initial manufacturing runs needed to start a subsequent trial.
• Planning activities for nimacimab's later stage studies.
• Host a conference call on November 10, 2025, to discuss Q3 2025 results.

Key Dates

Recommendation

The positive Phase 2a clinical data for nimacimab, particularly its synergistic effect with semaglutide in achieving greater weight loss, improved body composition, and significantly reduced weight rebound, represents a major de-risking event for Skye Bioscience. The clean safety profile is also a critical advantage in the obesity drug market. While the company reported an increased net loss due to higher R&D, the extended cash runway into 2027 provides sufficient capital for continued development. This strong clinical validation, coupled with a clear development pathway, positions the company favorably for future growth and potential partnerships in a high-demand therapeutic area.

Keywords

Skye Bioscience, SKYE, Obesity, Weight Loss, Nimacimab, Semaglutide, GLP-1, Phase 2a, Clinical Trial, Biotechnology, Metabolic Health, Q3 2025 Earnings, Financial Results, Drug Development, CB1 inhibitor